IP Library › Granted Patent US 8,178,128
Granted Patent B2
US 8,178,128 · App. 10/497,783 · Granted May 15, 2012

Nanoparticles containing polymeric nucleic acid homologs

Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,128
App. No.
10/497,783
Granted
May 15, 2012
Kind
B2
Abstract

A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.

Claims (8)

1. Nanoparticles comprising:

(a) a biodegradable polymer PLGA [poly(DL-lactide-co-glycolide)] of a lactide:glycolide ratio of 50:50 in combination with a cationic or neutral liposomal formulation comprising DOSPA or a 1:1 ratio of DOTAP:DOPE;

(b) an isolated, bioactive nucleic acid sequence encapsulated within the PLGA, wherein said nanoparticles are capable of releasing said isolated, bioactive nucleic acid sequence over an extended period of time; and

(c) the amino acid-sequence as set forth in SEQ ID NO:25.

2. The nanoparticles of claim 1 , wherein said nanoparticles further comprise a salt of a divalent cation.

3. The nanoparticles of claim 2 , wherein said divalent cation is calcium.

4. The nanoparticles of claim 1 , wherein the amino acid sequence is operative to impart to said nanoparticles a specific affinity for at least one target selected from the group consisting of an LDL receptor and a GAG-binding region of apoB-100.

5. The nanoparticles of claim 1 , further including mannitol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2004
From: GOLOMB, GERSHON; SACKS, HAGIT; NAJAREH, YOUSEF; FISHBEIN, ELIA; CHORNY, MICHAEL
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HERBREW UNIVERSITY OF JERUSALEM
Reel/Frame 016413/0439 →
Continuity (2)
Provisional Application 60335837 · Dec 5, 2001
Related Publication 20060051426A1 · Mar 9, 2006